Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Specific vs Empirical Anthelminthic Treatment for Eosinophilia
NCT06265870Recruiting
- Sponsor
- Prince of Songkla University
- Start
- May 2024
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of albendazole and ivermectin in eosinophilia (2 arms), sponsored by Prince of Songkla University. Primary endpoint: Eosinophilia recovery at 4 weeks. Started May 2024; status: recruiting.
02
Drugs
albendazoleivermectin
03
Conditions
eosinophilia
Beyond the preview
Go deeper on NCT06265870.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06265870.